| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | | | ||
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | 3 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 33 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | 38 | | | |
| | | | | 38 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 48 | | | |
| | | | | | |
Proposal | | | Voting Choices and Board Recommendation | |
Proposal 1: Election of Directors | | | • vote in favor of all nominees; | |
| • withhold authority to vote for all nominees; or | | ||
| • withhold authority to vote for any specified nominee. | | ||
| The Board recommends a vote FOR each of the nominees. | | ||
Proposal 2: Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our Common Stock, $0.01 par value per share, from 100,000,000 to 200,000,000 | | | • vote in favor of approval; | |
| • vote against approval; or | | ||
| • abstain from voting on approval. | | ||
| The Board recommends a vote FOR approval. | | ||
Proposal 3: Approval of our 2018 Employee Stock Purchase Plan and the authorization of 500,000 shares of our Common Stock to be available for issuance under the plan | | | • vote in favor of approval; | |
| • vote against approval; or | | ||
| • abstain from voting on approval. | | ||
| The Board recommends a vote FOR approval. | | ||
Proposal 4: Approval of an amendment to our to 2014 Equity Incentives Plan to increase the number of authorized shares of Common Stock available for issuance pursuant to future awards made under the plan by 3,750,000 | | | • vote in favor of approval; | |
| • vote against approval; or | | ||
| • abstain from voting on approval. | | ||
| The Board recommends a vote FOR approval. | | ||
Proposal 5: Ratification of Selection of Independent Registered Public Accounting Firm | | | • vote in favor of ratification; | |
| • vote against ratification; or | | ||
| • abstain from voting on ratification. | | ||
| The Board recommends a vote FOR ratification. | | ||
Proposal | | | • vote in favor of proposal; | |
| • vote against proposal; or | | ||
| • abstain from voting on proposal. | | ||
| The Board recommends a vote FOR the advisory vote to approve executive compensation. | |
Proposal | | | Abstentions | | | Broker Non-Votes | |
Proposal 1: Election of Directors | | | N/A | | | Not counted and no effect on vote. | |
Proposal 2: Approval of an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our Common Stock, $0.01 par value per share, from 100,000,000 to 200,000,000 | | | Effect of a vote AGAINST | | | N/A | |
Proposal 3: Approval of our 2018 Employee Stock Purchase Plan | | | Not counted and no effect on vote. | | | Not counted and no effect on vote. | |
Proposal 4: Approval of an amendment to our to 2014 Equity Incentives Plan to increase the number of authorized shares of Common Stock available for issuance pursuant to future awards made under the plan by 3,750,000 | | | Not counted and no effect on vote. | | | Not counted and no effect on vote. | |
Proposal 5: Ratification of Selection of Independent Registered Public Accounting Firm | | | Not counted and no effect on vote. | | | N/A | |
Proposal | | | Not counted and no effect on vote. | | | Not counted and no effect on vote. | |
| | | Timothy C. Barabe (1) | | | Susan L. Kelley (3) | | | Ronald M. Lindsay (3) | | | Michael D. Loberg (2)(3) | | | William G. Messenger (1)(2) | | | Ran Nussbaum | | | Paolo Pucci | | | Patrick J. Zenner (1)(2) | | ||||||||||||||||||||||||||||||
High level of financial literacy | | | | | X | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | | | |||||||
Relevant biotechnology business experience | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | ||||||
Extensive knowledge of drug research and development | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | ||||||
Extensive knowledge of drug commercialization and marketing | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | | | | | | | | | | | | X | | | | | | X | | | ||||||||
Expertise in corporate governance and business ethics | | | | | X | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | | | |||||||
Diversity of background, professional experience or culture | | | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | | | | | | | |
Name | | Fees Earned or Paid in Cash ($) | | Option Awards(1) ($) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Option Awards(1)($) | | Total ($) | | ||||||||||||||||||||||||
Timothy C. Barabe(2) | | | $ | 62,250 | | | | $ | 17,160 | | | | $ | 79,410 | | | | | $ | 57,000 | | | | $ | 14,060 | | | | $ | 71,060 | | | ||||||
Susan L. Kelley, M.D | | | | 56,000 | | | | | 17,160 | | | | | 73,160 | | | ||||||||||||||||||||||
Ronald M. Lindsay, Ph.D | | | | 74,000 | | | | | 17,160 | | | | | 91,160 | | | ||||||||||||||||||||||
Susan L. Kelley, M.D. | | | | 49,500 | | | | | 14,060 | | | | | 63,560 | | | ||||||||||||||||||||||
Ronald M. Lindsay, Ph.D. . | | | | 67,000 | | | | | 14,060 | | | | | 81,060 | | | ||||||||||||||||||||||
Michael D. Loberg, Ph.D.(3) | | | | 62,250 | | | | | 17,160 | | | | | 79,410 | | | | | | 55,750 | | | | | 14,060 | | | | | 69,810 | | | ||||||
William G. Messenger, D. Min. | | | | 68,500 | | | | | 17,160 | | | | | 85,660 | | | | | | 64,500 | | | | | 14,060 | | | | | 78,560 | | | ||||||
Ran Nussbaum(4) | | | | 6,250 | | | | | 18,459 | | | | | 24,709 | | | ||||||||||||||||||||||
Patrick J. Zenner | | | | 73,500 | | | | | 28,600 | | | | | 102,100 | | | | | | 69,500 | | | | | 17,575 | | | | | 87,075 | | |
Name and Principal Position | | 2014 Annualized Base Salary ($) | | 2015 Annualized Base Salary ($) | | % Increase | | Comment | | | 2016 Annualized Base Salary ($) | | 2017 Annualized Base Salary ($) | | % Increase | | Comment | | ||||||||||||||||||||||||||
Paolo Pucci, CEO | | | | 489,000 | | | | | 489,000 | | | | | — | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | | | | 489,000 | | | | | 499,000 | | | | | 2.0 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | ||||||||
Peter S. Lawrence, COO | | | | 414,000 | | | | | 422,000 | | | | | 2.0 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | | | | 431,000 | | | | | 448,000 | | | | | 4.0 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | ||||||||
Dr. Brian Schwartz, CMO | | | | 396,000 | | | | | 412,000 | | | | | 4.0 | | | Base salary negotiated in and adjusted per employment agreement and annual review. | | | | | 429,000 | | | | | 446,000 | | | | | 4.0 | | | Base salary negotiated in and adjusted per employment agreement and annual review. | | ||||||||
Robert J. Weiskopf, CFO | | | | 258,750 | | | | | 305,000 | | | | | 17.9 | | | Merit increase with additional responsibility, and increase to $305,000 related to promotion to Chief Financial Officer and Treasurer in June 2015. | | | | | 305,000 | | | | | 317,000 | | | | | 4.0 | | | Base salary adjusted at annual review. | |
Name and Principal Position | | | (% of Base Salary) | | | (% of Base Salary) | | | Comment | |
Paolo Pucci, CEO | | | 60.0% | | | | | Target bonus set by terms of amended employment agreement. Actual bonus | | |
Peter S. Lawrence, COO | | | 45.0% | | | | | Target bonus set by terms of amended employment agreement. Actual bonus | | |
Dr. Brian Schwartz, CMO | | | 40.0% | | | | | Target bonus set by terms of employment agreement. Actual bonus | | |
Robert J. Weiskopf, CFO | | | | | | | Bonus target set by Compensation Committee in accordance with annual standard process. Actual bonus 83% of target. | |
Name and Principal Position | | Year | | Salary ($) (1) | | Bonus ($) | | Stock Awards ($) | | Option Awards ($) (2) | | Non-Equity Incentive Plan Compensation ($) (3) | | All Other Compensation ($) (4) | | Total ($) | | Year | | Salary ($) (1) | | Bonus ($) | | Stock Awards ($) | | Option Awards ($) (2) | | Non-Equity Incentive Plan Compensation ($) (3) | | All Other Compensation ($) (4) | | Total ($) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paolo Pucci Chief Executive Officer | | | | | 2015 | | | | | 489,345 | | | | | — | | | | | — | | | | | 285,948 | | | | | 293,607 | | | | | 8,550 | | | | | 1,077,450 | | | | | 2017 | | | | | 498,718 | | | | | — | | | | | — | | | | | 634,860 | | | | | 248,568 | | | | | 8,742 | | | | | 1,390,888 | ||||||||||||||
| | | 2014 | | | | | 489,345 | | | | | — | | | | | — | | | | | 532,134 | | | | | 249,566 | | | | | 8,400 | | | | | 1,279,445 | | | | 2016 | | | | | 489,345 | | | | | — | | | | | — | | | | | 548,208 | | | | | 255,438 | | | | | 8,550 | | | | | 1,301,541 | |||||||||||||||||
| | | 2013 | | | | | 489,345 | | | | | — | | | | | — | | | | | 486,609 | | | | | 249,566 | | | | | 8,100 | | | | | 1,233,620 | | | | 2015 | | | | | 489,345 | | | | | — | | | | | — | | | | | 285,948 | | | | | 293,607 | | | | | 8,550 | | | | | 1,077,450 | |||||||||||||||||
Peter S. Lawrence President, Chief Operating Officer, General Counsel and Secretary | | | | | 2015 | | | | | 421,562 | | | | | — | | | | | — | | | | | 160,571 | | | | | 189,990 | | | | | 8,550 | | | | | 780,673 | | | | | 2017 | | | | | 447,140 | | | | | — | | | | | — | | | | | 350,267 | | | | | 167,279 | | | | | 8,742 | | | | | 973,428 | ||||||||||||||
| | | 2014 | | | | | 413,921 | | | | | — | | | | | — | | | | | 245,130 | | | | | 158,325 | | | | | 8,400 | | | | | 825,776 | | | | 2016 | | | | | 430,286 | | | | | — | | | | | — | | | | | 274,104 | | | | | 168,597 | | | | | 8,550 | | | | | 881,536 | |||||||||||||||||
| | | 2013 | | | | | 413,921 | | | | | — | | | | | — | | | | | 210,864 | | | | | 158,325 | | | | | 8,100 | | | | | 791,210 | | | | 2015 | | | | | 421,562 | | | | | — | | | | | — | | | | | 160,571 | | | | | 189,990 | | | | | 8,550 | | | | | 780,673 | |||||||||||||||||
Dr. Brian Schwartz Chief Medical Officer and Senior Vice President | | | | | 2015 | | | | | 410,991 | | | | | — | | | | | — | | | | | 107,780 | | | | | 164,884 | | | | | 8,550 | | | | | 692,205 | | | | | 2017 | | | | | 445,121 | | | | | — | | | | | — | | | | | 275,106 | | | | | 148,021 | | | | | 8,742 | | | | | 876,991 | ||||||||||||||
| | | 2014 | | | | | 394,597 | | | | | — | | | | | — | | | | | 185,811 | | | | | 134,761 | | | | | 8,400 | | | | | 723,569 | | | | 2016 | | | | | 428,001 | | | | | — | | | | | — | | | | | 237,557 | | | | | 149,187 | | | | | 8,550 | | | | | 823,295 | |||||||||||||||||
| | | 2013 | | | | | 380,258 | | | | | — | | | | | — | | | | | 145,983 | | | | | 129,578 | | | | | 8,100 | | | | | 663,919 | | | | 2015 | | | | | 410,991 | | | | | — | | | | | — | | | | | 107,780 | | | | | 164,884 | | | | | 8,550 | | | | | 692,205 | |||||||||||||||||
Robert J. Weiskopf (5) Chief Financial Officer and Treasurer | | | | | 2015 | | | | | 288,372 | | | | | — | | | | | — | | | | | 91,876 | | | | | 106,750 | | | | | 8,550 | | | | | 495,548 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2017 | | | | | 316,684 | | | | | — | | | | | — | | | | | 183,369 | | | | | 105,310 | | | | | 8,742 | | | | | 614,105 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2016 | | | | | 305,000 | | | | | — | | | | | — | | | | | 137,052 | | | | | 92,873 | | | | | 8,550 | | | | | 543,475 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Robert J. Weiskopf Chief Financial Officer and Treasurer | | | | 2015 | | | | | 288,372 | | | | | — | | | | | — | | | | | 91,876 | | | | | 106,750 | | | | | 8,550 | | | | | 495,548 |
| | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | Grant Date Fair Value of Stock and Option Awards(2) ($) | | | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | Grant Date Fair Value of Stock and Option Awards ($) | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | Threshold ($) | | Target ($) | | Maximum ($) | | | Grant Date | | Threshold ($) | | Target ($) | | Maximum ($) | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paolo Pucci | | | | N/A | | | | | — | | | | | 293,607 | | | | | 440,410 | | | | | | | N/A | | | | | — | | | | | 303,971 | | | | | 455,957 | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 1/20/2015 | | | | | | | | | | | | | | | | | | | | 390,000 | | | | | 285,948 | | | | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 300,000 | | | | | 281,460 | | | | |||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 600,000 | | | | | 353,400 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peter S. Lawrence | | | | N/A | | | | | — | | | | | 193,789 | | | | | 290,684 | | | | | | | N/A | | | | | — | | | | | 206,579 | | | | | 309,869 | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 185,000 | | | | | 173,567 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/20/2015 | | | | | | | | | | | | | | | | | | | | 219,000 | | | | | 160,571 | | | | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 300,000 | | | | | 176,700 | | | | |||||||||||||||||||||||||||||
Dr. Brian Schwartz | | | | N/A | | | | | — | | | | | 171,480 | | | | | 257,219 | | | | | | | N/A | | | | | — | | | | | 182,797 | | | | | 274,195 | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 1/20/2015 | | | | | | | | | | | | | | | | | | | | 147,000 | | | | | 107,780 | | | | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 130,000 | | | | | 121,966 | | | | |||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 260,000 | | | | | 153,140 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Robert J. Weiskopf | | | | N/A | | | | | — | | | | | 106,750 | | | | | 160,125 | | | | | | | N/A | | | | | — | | | | | 130,052 | | | | | 195,078 | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 1/20/2015 | | | | | | | | | | | | | | | | | | | | 108,500 | | | | | 91,876 | | | | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 95,000 | | | | | 89,129 | | | | |||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 150,000 | | | | | 88,350 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Option Awards | | | | | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | ||||||||||||||||||||||||||||||||||||||||||
Paolo Pucci | | | | | 500,000(3) | | | | | | | | | $ | 3.95 | | | | | 6/9/2018 | | | | | | | | | | | | | | | | 500,000 | | | | | | | | | $ | 3.95 | | | | | 6/9/2018 | | | | | | | |||||||||||
| | | 225,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 100,000 | | | | | | | | | | 4.14 | | | | | 7/15/2020 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 300,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 236,250 | | | | | 78,750 | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 142,500 | | | | | 142,500 | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 76,250 | | | | | 228,750 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 390,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 390,000(4) | | | | $ | 1,614,600 | | | ||||||||||||||||||||||||||||||||||||||
| | | | 225,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 100,000 | | | | | | | | | | 4.14 | | | | | 7/15/2020 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 300,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 315,000 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 285,000 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 228,750 | | | | | 76,250 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 97,502 | | | | | 195,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 120,000 | | | | | 360,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 300,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 600,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
Peter S. Lawrence | | | | | 300,000 | | | | | | | | | | 6.20 | | | | | 4/13/2016 | | | | | | | | | | | | | | | | 200,000 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | |||||||||||
| | | 50,000 | | | | | | | | | | 6.16 | | | | | 1/16/2017 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 100,000 | | | | | | | | | | 7.56 | | | | | 10/4/2017 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 200,000 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 130,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 130,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 25,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 110,812 | | | | | 36,938 | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 61,750 | | | | | 61,750 | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 35,125 | | | | | 105,375 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 169,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 50,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 12,500(5) | | | | $ | 31,375 | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 125,000(6) | | | | $ | 307,500 | | | ||||||||||||||||||||||||||||||||||||||
| | | | 130,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 130,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 25,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 147,750 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 123,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 105,375 | | | | | 35,125 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 84,500 | | | | | 84,500 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 25,000 | | | | | 25,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 60,000 | | | | | 180,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 150,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 35,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 300,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
Dr. Brian Schwartz | | | | | 200,000 | | | | | | | | | | 3.62 | | | | | 7/14/2018 | | | | | | | | | | | | | | | | 200,000 | | | | | | | | | | 3.62 | | | | | 7/14/2018 | | | | | | | |||||||||||
| | | 90,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 90,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 50,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 82,125 | | | | | 27,375 | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 42,750 | | | | | 42,750 | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 26,625 | | | | | 79,875 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 117,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 30,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 50,000(7) | | | | $ | 375,000 | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 15,000(8) | | | | $ | 37,650 | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 120,000(7) | | | | $ | 295,200 | | | ||||||||||||||||||||||||||||||||||||||
| | | | 90,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 90,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 50,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 109,500 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 85,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 79,875 | | | | | 26,625 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 58,500 | | | | | 58,500 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 15,000 | | | | | 15,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 52,000 | | | | | 156,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 130,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 260,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | |
| | Option Awards | | | | | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | ||||||||||||||||||||||||||||||||||||||||||
Robert J. Weiskopf | | | | | 30,000 | | | | | | | | | | 6.81 | | | | | 2/19/2017 | | | | | | | | | | | | | | | | 22,500 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | |||||||||||
| | | 22,500 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 45,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 45,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 40,500 | | | | | | | | | | 7.95 | | | | | 2/01/2022 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 32,062 | | | | | 10,688 | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 24,125 | | | | | 24,125 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 14,625 | | | | | 43,875 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | 5,000 | | | | | 15,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | 30,000 | | | | | 1.80 | | | | | 6/01/2025 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | 3,200(9) | | | | $ | 8,032 | | | ||||||||||||||||||||||||||||||||||||||
| | | | 45,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 45,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 40,500 | | | | | | | | | | 7.95 | | | | | 2/01/2022 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 42,750 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 36,187 | | | | | 12,063 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 29,250 | | | | | 29,250 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 10,000 | | | | | 10,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 15,000 | | | | | 15,000 | | | | | 1.80 | | | | | 6/01/2025 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | 30,000 | | | | | 90,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 75,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 20,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | 160,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | |
| | Option Awards | | Stock Awards | | |||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of Securities Acquired on Exercise | | Value Realized Upon Exercise ($) | | Number of Shares Acquired on Vesting | | Value Realized on Vesting ($) (1) | | | Number of Securities Acquired on Exercise | | Value Realized Upon Exercise ($) | | Number of Shares Acquired on Vesting | | Value Realized on Vesting ($)(1) | | ||||||||||||||||||||||||||||||||
Peter S. Lawrence | | | | — | | | | | — | | | | | 6,250 | | | | | 7,500 | | | | | | — | | | | | — | | | | | 6,250 | | | | | 9,875 | | | ||||||||
Dr. Brian Schwartz | | | | — | | | | | — | | | | | 7,500 | | | | | 9,000 | | | | | | — | | | | | — | | | | | 7,500 | | | | | 11,850 | | | ||||||||
Robert J. Weiskopf | | | | — | | | | | — | | | | | 3,200 | | | | | 3,840 | | | | | | — | | | | | — | | | | | 3,200 | | | | | 5,056 | | |
Name | | Cash Payment(1) ($) | | Equity Acceleration(2) ($) | | Benefits and Perquisites(3) ($) | | Total ($) | | | Cash Payment(1) ($) | | Equity Acceleration ($) | | Benefits and Perquisites(2) ($) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Pucci | | | $ | 1,477,822 | | | | | 1,240,200 | | | | $ | 28,060 | | | | $ | 2,746,082 | | | | | $ | 1,540,439 | | | | $ | 551,550 | | | | $ | 48,870 | | | | $ | 2,140,859 | | | ||||||||
Peter S. Lawrence | | | | 612,188 | | | | | 519,565 | | | | | 28,060 | | | | | 1,159,813 | | | | | | 649,410 | | | | | 285,855 | | | | | 24,435 | | | | | 959,700 | | | ||||||||
Dr. Brian Schwartz | | | | 577,095 | | | | | 549,920 | | | | | 28,060 | | | | | 1,155,075 | | | | | | 624,186 | | | | | 233,615 | | | | | 24,435 | | | | | 882,236 | | |
Name of Individual or Identity of Group and Position | | | Number of Shares Underlying Options | | |||
Named Executive Officers and Current Executive Officers | | | | | | | |
Paulo Pucci, Chief Executive Officer | | | | | 249,000 | | |
Peter S. Lawrence, President and Chief Operating Officer | | | | | 124,500 | | |
Brian Schwartz, Chief Medical Officer | | | | | 107,900 | | |
Robert J. Weiskopf, Chief Financial Officer | | | | | 62,250 | | |
All current executive officers, as a group (4 persons) | | | | | 543,650 | | |
Non-Employee Directors and Non-Executive Officers | | | | | | | |
All current non-employee directors and director nominees, as a group | | | | | — | | |
All non-executive officer employees as a group | | | | | 177,620 | | |
| | 2015 | | 2014 | | | 2017 | | 2016 | | ||||||||||||||||
Audit Fees | | | $ | 410,000 | | | | $ | 427,000 | | | | | $ | 544,000 | | | | $ | 490,000 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | |||||||||||||||
Tax Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
All Other Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Total | | | $ | 410,000 | | | | $ | 427,000 | | | | | $ | 544,000 | | | | $ | 490,000 | | | |
Name | | Common Stock Owned | | Options to Purchase Common Stock | | Total Stock and Stock-based Holdings | | Percent of Class | | | Common Stock Owned | | Options to Purchase Common Stock | | Total Stock and Stock-based Holdings | | Percent of Class | | ||||||||||||||||||||||||||||||||
First Eagle Investment Management, LLC(1) 1345 Avenue of the Americas New York, NY 10105 | | | | 10,825,233 | | | | | 935,673 | | | | | 11,760,906 | | | | | 16.6% | | | | | | 14,733,484 | | | | | — | | | | | 14,733,484 | | | | | 16.9% | | | ||||||||
Nantahala Capital Management, LLC(2) 19 Old Kings Highway S, Suite 200 Darien, CT 06820 | | | | 8,615,547 | | | | | 1,053,333 | | | | | 9,668,880 | | | | | 13.6% | | | | | | 12,222,130 | | | | | — | | | | | 12,222,130 | | | | | 14.0% | | | ||||||||
BVF Partners, LP(3) 900 North Michigan Avenue, Suite 1100 Chicago, IL 60611 | | | | 7,862,478 | | | | | 467,868 | | | | | 8,330,316 | | | | | 11.7% | | | | | | 16,434,912 | | | | | — | | | | | 16,434,912 | | | | | 18.9% | | | ||||||||
1Globe Capital LLC(4) 245 First Street Riverview II, 18th Floor Cambridge, MA 02142 | | | | 4,008,664 | | | | | — | | | | | 4,008,664 | | | | | 5.6% | | |
Directors and Executive Officers(1) | | Common Stock Owned | | Options to Purchase Common Stock | | Total Stock and Stock-based Holdings | | Percent of Class | | | Common Stock Owned | | Options to Purchase Common Stock | | Total Stock and Stock-based Holdings | | Percent of Class | | ||||||||||||||||||||||||||||||||
Timothy C. Barabe(2) | | | | 113,331 | | | | | 130,000 | | | | | 243,331 | | | | | * | | | | | | 136,897 | | | | | 130,000 | | | | | 266,897 | | | | | * | | | ||||||||
Susan L. Kelley | | | | 50,000 | | | | | 105,000 | | | | | 155,000 | | | | | * | | | | | | 50,000 | | | | | 125,000 | | | | | 175,000 | | | | | * | | | ||||||||
Ronald M. Lindsay | | | | 20,000 | | | | | 130,000 | | | | | 150,000 | | | | | * | | | | | | 20,000 | | | | | 130,000 | | | | | 150,000 | | | | | * | | | ||||||||
Michael D. Loberg | | | | 136,674 | | | | | 140,000 | | | | | 276,674 | | | | | * | | | | | | 162,514 | | | | | 130,000 | | | | | 292,514 | | | | | * | | | ||||||||
William G. Messenger | | | | 10,000 | | | | | 130,000 | | | | | 140,000 | | | | | * | | | | | | 10,000 | | | | | 130,000 | | | | | 140,000 | | | | | * | | | ||||||||
Ran Nussbaum(3) | | | | — | | | | | — | | | | | — | | | | | * | | | |||||||||||||||||||||||||||||
Patrick J. Zenner | | | | 73,770 | | | | | 210,000 | | | | | 283,770 | | | | | * | | | | | | 73,770 | | | | | 205,000 | | | | | 278,770 | | | ��� | | * | | | ||||||||
Peter S. Lawrence | | | | 74,365 | | | | | 1,300,375 | | | | | 1,374,740 | | | | | 1.9% | | | | | | 77,743 | | | | | 1,027,250 | | | | | 1,104,993 | | | | | 1.3% | | | ||||||||
Paolo Pucci | | | | 410,614 | | | | | 1,806,252 | | | | | 2,216,866 | | | | | 3.1% | | | | | | 485,364 | | | | | 2,540,002 | | | | | 3,025,366 | | | | | 3.5% | | | ||||||||
Brian Schwartz | | | | 52,016 | | | | | 693,625 | | | | | 745,641 | | | | | 1.0% | | | | | | 63,886 | | | | | 978,250 | | | | | 1,042,136 | | | | | 1.2% | | | ||||||||
Robert J. Weiskopf | | | | 28,422 | | | | | 258,812 | | | | | 287,234 | | | | | * | | | | | | 30,407 | | | | | 379,125 | | | | | 409,532 | | | | | * | | | ||||||||
Directors and executive officers as a group (10 persons) | | | | 969,192 | | | | | 4,904,064 | | | | | 5,873,256 | | | | | 8.3% | | | |||||||||||||||||||||||||||||
Directors and executive officers as a group (11 persons) | | | | 1,110,581 | | | | | 5,774,627 | | | | | 6,885,208 | | | | | 7.9% | | | |